Benzimidazole compounds or their salts, canine heartworm disease control agents containing said compounds, and methods of using the same

A benzimidazole compound with an imidazole group at the 2-position effectively controls heartworms in dogs, overcoming resistance concerns and reducing the need for continuous treatment.

JP7595160B2Active Publication Date: 2024-12-05NIHON NOHYAKU CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2023525917
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-02-15
Filing Date
2022-06-02
Publication Date
2024-12-05
Estimated Expiration
2042-06-02

AI Technical Summary

Technical Problem

Current heartworm disease control agents for dogs, such as melarsomine dihydrochloride, face challenges with long-term use leading to drug resistance and require year-round administration, necessitating the development of new drugs with improved efficacy against heartworms.

Method used

A benzimidazole compound with an imidazole group at the 2-position, represented by a specific general formula, is developed as a heartworm disease control agent, offering effective control against both mature and immature heartworms.

Benefits of technology

The benzimidazole compound demonstrates excellent control effects on heartworm disease in dogs, addressing resistance issues and providing effective prevention and treatment without the need for continuous administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595160000001
    Figure 0007595160000001
  • Figure 0007595160000002
    Figure 0007595160000002
  • Figure 0007595160000003
    Figure 0007595160000003
Patent Text Reader

Abstract

The present invention addresses the problem of providing a canine filariasis control agent for animals that exerts excellent efficacy when administered to a target animal, and a method of the use of a canine filariasis control agent in a target animal with the use of aforesaid agent. The present invention provides a benzimidazole compound represented by general formula (1) [wherein: R represents a hydrogen atom, etc.; X1, X3, Y1, Y2, Y3 and Y4 represent a hydrogen atom, etc.; and X2 represents a substituted phenylalkyl group, etc.] or a salt thereof, a canine filariasis control agent for animals comprising the same as an active ingredient, a method of the use thereof, etc.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to a benzimidazole compound or a salt thereof, an agent for controlling heartworm disease in animals containing the compound as an active ingredient, and a method for using the agent. [Background technology]

[0002] Heartworm infection is caused by the mosquito-borne parasite Dirofilaria immitis and affects many animal species and pets. The mechanism of infection is as follows: mosquitoes ingest microfilariae (the new larval stage), which then molt repeatedly within the body and develop into infective larvae (L3). As the mosquito feeds, the infective larvae reach the host's skin, where they penetrate and begin to develop inside the animal. Within 3 to 12 days, the infective larvae molt to the fourth stage (L4). After remaining in the subcutaneous tissue, abdomen, and chest for approximately two months, the L4 larvae undergo a final molt to become young adults, which reach the host's heart and pulmonary arteries approximately 70 to 120 days after initial infection.

[0003] On the other hand, it has been reported that benzimidazole compounds having a pyridyl group at the 2-position are effective in controlling ectoparasites or endoparasites in animals (see, for example, Patent Document 1), but this document does not disclose any description of benzimidazole compounds having an imidazole group at the 2-position or the insecticidal effect of such compounds against heartworms. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2019 / 225663 Brochure Summary of the Invention [Problem to be solved by the invention]

[0005] Melarsomine dihydrochloride is a known anti-heartworm agent, effective against both mature and immature heartworms. Heartworm infection can be prevented with macrolide prophylactics, but year-round prevention is recommended regardless of the animal's living conditions. However, long-term use of these drugs in animals raises concerns about the development of resistance to existing drugs. Therefore, there is a need for new drugs that are active against heartworms and can be used to treat heartworm infection. [Means for solving the problem]

[0006] As a result of intensive research to solve the above-mentioned problems, the present inventors have found that a benzimidazole compound having an imidazole group at the 2-position, represented by general formula (1), or a salt thereof, not only has an excellent effect in controlling canine heartworm disease, but can also solve the above-mentioned problems, thereby completing the present invention. That is, the present invention is [1] General formula (1) [ka] {In the formula, R is (a1) a hydrogen atom; (a2) a (C1-C6) alkyl group; (a3) ​​a halo(C1-C6) alkyl group; (a4) a (C2-C6) alkenyl group; (a5) a (C2-C6) alkynyl group; (a6) a (C1-C6) alkoxy(C1-C6) alkyl group; (a7) a (C1-C6) alkylthio(C1-C6) alkyl group; (a8) a (C1-C6) alkoxycarbonyl(C1-C6) alkyl group; (a9) a (C1-C6) alkoxycarbonyl group; (a10) an aryl(C1-C6) alkyl group; or (a11). (a12) an aryl(C1-C6)alkyl group having 1 to 5 substituents, which may be the same or different, selected from (a) a halogen atom, (b) a (C1-C6)alkyl group, (c) a halo(C1-C6)alkyl group, (d) a (C1-C6)alkoxy group, (e) a halo(C1-C6)alkoxy group, (f) a (C1-C6)alkylthio group, (g) a halo(C1-C6)alkylthio group, (h) a (C1-C6)alkylsulfinyl group, (i) a halo(C1-C6)alkylsulfinyl group, (j) a (C1-C6)alkylsulfonyl group, (k) a halo(C1-C6)alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (a13) (a14) R 3 R 4 N group (where R 3 and R 4may be the same or different and represent (aa) a hydrogen atom, (ab) a (C1-C6) alkyl group, (ac) a (C1-C6) alkoxy group, (ad) a (C1-C6) alkoxycarbonyl group, (ae) a (C1-C6) alkylsulfonyl group, (af) a halo(C1-C6) alkylsulfonyl group, or (ag) a phenyl group; (a15) R 3 R 4 N carbonyl group (where R 3 and R 4 is the same as above. );(a16) R 3 R 4 N-thiocarbonyl group (where R 3 and R 4 is the same as above. ); or (a17) R 3 R 4 N sulfonyl group (where R 3 and R 4 indicates the same as above. X 1 and X 3 may be the same or different and represent (b1) a hydrogen atom; (b2) a halogen atom; or (b3) a (C1-C6) alkyl group. X 2(c1) a (C1-C8) alkyl group; (c2) a (C2-C8) alkenyl group; (c3) a (C2-C8) alkynyl group; (c4) an aryl group; (c5) an aryl group having 1 to 5 substituents, which may be the same or different, selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (l) a nitro group, and (m) a trimethylsilyl group; (c6) an aryl(C1-C6) alkyl group; or (c7) and (c) an aryl(C1-C6)alkyl group having 1 to 5 substituents, which may be the same or different, selected from (a) a halogen atom, (b) a (C1-C6)alkyl group, (c) a halo(C1-C6)alkyl group, (d) a (C1-C6)alkoxy group, (e) a halo(C1-C6)alkoxy group, (f) a (C1-C6)alkylthio group, (g) a halo(C1-C6)alkylthio group, (h) a (C1-C6)alkylsulfinyl group, (i) a halo(C1-C6)alkylsulfinyl group, (j) a (C1-C6)alkylsulfonyl group, (k) a halo(C1-C6)alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group. Y 1 and Y 4 may be the same or different and represent (d1) a hydrogen atom; (d2) a halogen atom; or (d3) a (C1-C6) alkyl group. Y 2 and Y 3may be the same or different, and are (e1) a hydrogen atom; (e2) a halogen atom; (e3) a (C1-C6) alkyl group; (e4) a (C1-C6) alkoxy group; (e5) a (C1-C6) alkylthio group; (e6) a halo(C1-C6) alkyl group; (e7) a halo(C1-C6) alkoxy group; (e8) an aryloxy group; (e9) an aryloxy group having 1 to 5 substituents, which may be the same or different, selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (j) a (C1-C6) alkylsulfonyl group, (k) a halo(C1-C6) alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (e10) an arylthio group; and (e11) an arylthio group having 1 to 5 substituents, which may be the same or different, selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (j) a (C1-C6) alkylsulfonyl group, (k) a halo(C1-C6) alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (e12) an arylcarbonyl group;or (e13) an arylcarbonyl group having 1 to 5 substituents, which may be the same or different, selected from (a) a halogen atom, (b) a (C1-C6)alkyl group, (c) a halo(C1-C6)alkyl group, (d) a (C1-C6)alkoxy group, (e) a halo(C1-C6)alkoxy group, (f) a (C1-C6)alkylthio group, (g) a halo(C1-C6)alkylthio group, (h) a (C1-C6)alkylsulfinyl group, (i) a halo(C1-C6)alkylsulfinyl group, (j) a (C1-C6)alkylsulfonyl group, (k) a halo(C1-C6)alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group;}; or a salt thereof, [2] R is (a1) a hydrogen atom; (a2) a (C1-C6) alkyl group; (a3) ​​a halo(C1-C6) alkyl group; (a4) a (C2-C6) alkenyl group; (a5) a (C2-C6) alkynyl group; (a6) a (C1-C6) alkoxy(C1-C6) alkyl group; (a7) a (C1-C6) alkylthio(C1-C6) alkyl group; (a8) a (C1-C6) alkoxycarbonyl(C1-C6) alkyl group; (a9) a (C1-C6) alkoxycarbonyl group; (a10) an aryl(C1-C6) alkyl group; (a12) an aryl(C1-C6) alkoxy(C1-C6) alkyl group; or (a15) R 3 R 4 N carbonyl group (where R 3 and R 4 is the same as above. );(a16) R 3 R 4 N-thiocarbonyl group (where R 3 and R 4 is the same as above. ); or (a17) R 3 R 4 N sulfonyl group (where R 3 and R 4 indicates the same as above. X 1 and X 3 Both indicate (b1) a hydrogen atom; X 2(c1) a (C1-C8) alkyl group; (c3) a (C2-C8) alkynyl group; (c5) an aryl group having 1 to 5 substituents, which may be the same or different, selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (l) a nitro group, and (m) a trimethylsilyl group; or (c7). an aryl(C1-C6)alkyl group having 1 to 5 substituents, which may be the same or different, selected from (a) a halogen atom, (b) a (C1-C6)alkyl group, (c) a halo(C1-C6)alkyl group, (d) a (C1-C6)alkoxy group, (e) a halo(C1-C6)alkoxy group, (f) a (C1-C6)alkylthio group, (g) a halo(C1-C6)alkylthio group, (h) a (C1-C6)alkylsulfinyl group, (i) a halo(C1-C6)alkylsulfinyl group, (j) a (C1-C6)alkylsulfonyl group, (k) a halo(C1-C6)alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; Y 1 and Y 4 may be the same or different and represent (d1) a hydrogen atom; (d2) a halogen atom; or (d3) a (C1-C6) alkyl group; Y 2 and Y 3 may be the same or different and represent (e1) a hydrogen atom; (e2) a halogen atom; (e3) a (C1-C6) alkyl group; (e5) a (C1-C6) alkylthio group; (e6) a halo(C1-C6) alkyl group; (e7) a halo(C1-C6) alkoxy group; (e8) an aryloxy group; (e10) an arylthio group; or (e12) an arylcarbonyl group. [1] A benzimidazole compound or a salt thereof [3] A canine heartworm disease control agent for animals, comprising the benzimidazole compound or salt thereof according to any one of [1] and [2] as an active ingredient. [4] A method for using an agent for controlling canine heartworm disease for animals, which comprises administering an effective amount of the benzimidazole compound or salt thereof according to any one of [1] and [2] to an animal. Regarding. [Effects of the Invention]

[0007] The benzimidazole compound or salt thereof having an imidazole group at the 2-position of the present invention has excellent efficacy as an agent for controlling canine heartworm disease. DETAILED DESCRIPTION OF THE INVENTION

[0008] In the definition of the general formula (1) of the benzimidazole compound or salt thereof having an imidazole group at the 2-position of the present invention, "halo" means "halogen atom" and represents a fluorine atom, chlorine atom, bromine atom, or iodine atom.

[0009] The term "(C1-C6) alkyl group" refers to a linear or branched alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, a normal propyl group, an isopropyl group, a normal butyl group, an isobutyl group, a secondary butyl group, a tertiary butyl group, a normal pentyl group, an isopentyl group, a tertiary pentyl group, a neopentyl group, a 2,3-dimethylpropyl group, a 1-ethylpropyl group, a 1-methylbutyl group, a 2-methylbutyl group, a normal hexyl group, an isohexyl group, a 2-hexyl group, a 3-hexyl group, a 2-methylpentyl group, a 3-methylpentyl group, a 1,1,2-trimethylpropyl group, or a 3,3-dimethylbutyl group; The term "(C2-C6) alkenyl group" refers to a linear or branched alkenyl group having 2 to 6 carbon atoms, such as a vinyl group, an allyl group, an isopropenyl group, a 1-butenyl group, a 2-butenyl group, a 2-methyl-2-propenyl group, a 1-methyl-2-propenyl group, a 2-methyl-1-propenyl group, a pentenyl group, a 1-hexenyl group, or a 3,3-dimethyl-1-butenyl group; The term "(C2-C6)alkynyl group" refers to a straight-chain or branched-chain alkynyl group having 2 to 6 carbon atoms, such as an ethynyl group, a 1-propynyl group, a 2-propynyl group, a 1-butynyl group, a 2-butynyl group, a 3-butynyl group, a 3-methyl-1-propynyl group, a 2-methyl-3-propynyl group, a pentynyl group, or a 1-hexynyl group.

[0010] The term "(C1-C6)alkoxy group" refers to a straight-chain or branched-chain alkoxy group having 1 to 6 carbon atoms, such as a methoxy group, an ethoxy group, a normal propoxy group, an isopropoxy group, a normal butoxy group, a secondary butoxy group, a tertiary butoxy group, a normal pentyloxy group, an isopentyloxy group, a tertiary pentyloxy group, a neopentyloxy group, a 2,3-dimethylpropyloxy group, a 1-ethylpropyloxy group, a 1-methylbutyloxy group, or a normal hexyloxy group.

[0011] Examples of the "(C1-C6) alkylthio group" include a linear or branched alkylthio group having 1 to 6 carbon atoms, such as a methylthio group, an ethylthio group, a normal propylthio group, an isopropylthio group, a normal butylthio group, a secondary butylthio group, a tertiary butylthio group, a normal pentylthio group, an isopentylthio group, a tertiary pentylthio group, a neopentylthio group, a 2,3-dimethylpropylthio group, a 1-ethylpropylthio group, a 1-methylbutylthio group, a normal hexylthio group, an isohexylthio group, and a 1,1,2-trimethylpropylthio group; Examples of the "(C1-C6) alkylsulfinyl group" include linear or branched alkylsulfinyl groups having 1 to 6 carbon atoms, such as a methylsulfinyl group, an ethylsulfinyl group, a normal propylsulfinyl group, an isopropylsulfinyl group, a normal butylsulfinyl group, a secondary butylsulfinyl group, a tertiary butylsulfinyl group, a normal pentylsulfinyl group, an isopentylsulfinyl group, a tertiary pentylsulfinyl group, a neopentylsulfinyl group, a 2,3-dimethylpropylsulfinyl group, a 1-ethylpropylsulfinyl group, a 1-methylbutylsulfinyl group, a normal hexylsulfinyl group, an isohexylsulfinyl group, and a 1,1,2-trimethylpropylsulfinyl group; Examples of the "(C1-C6) alkylsulfonyl group" include linear or branched alkylsulfonyl groups having 1 to 6 carbon atoms, such as methylsulfonyl, ethylsulfonyl, normal propylsulfonyl, isopropylsulfonyl, normal butylsulfonyl, secondary butylsulfonyl, tertiary butylsulfonyl, normal pentylsulfonyl, isopentylsulfonyl, tertiary pentylsulfonyl, neopentylsulfonyl, 2,3-dimethylpropylsulfonyl, 1-ethylpropylsulfonyl, 1-methylbutylsulfonyl, normal hexylsulfonyl, isohexylsulfonyl, and 1,1,2-trimethylpropylsulfonyl.

[0012] The above "(C1-C6) alkyl group," "(C2-C6) alkenyl group," "(C2-C6) alkynyl group," "(C1-C6) alkoxy group," "(C1-C8) alkylthio group," "(C1-C6) alkylsulfinyl group," or "(C1-C6) alkylsulfonyl group" may be substituted with one or more halogen atoms at any substitutable position, and when two or more halogen atoms are substituted, the halogen atoms may be the same or different. These are respectively represented as "halo(C1-C6) alkyl group," "halo(C2-C6) alkenyl group," "halo(C2-C6) alkynyl group," "halo(C1-C6) alkoxy group," "halo(C1-C6) alkylthio group," "halo(C1-C6) alkylsulfinyl group," or "halo(C1-C6) alkylsulfonyl group."

[0013] Expressions such as "(C1-C6)", "(C2-C6)", etc. indicate the range of carbon atoms of various substituents. Furthermore, the above definitions can also be applied to groups to which the above substituents are linked. For example, "(C1-C6)alkoxy(C1-C6)alkyl" indicates that a linear or branched alkoxy group having 1 to 6 carbon atoms is linked to a linear or branched alkyl group having 1 to 6 carbon atoms.

[0014] The term "(C1-C6)alkoxycarbonyl group" refers to an alkoxycarbonyl group composed of a straight-chain or branched alkoxy group having 1 to 6 carbon atoms and a carbonyl group, such as a methoxycarbonyl group, ethoxycarbonyl group, normal propoxycarbonyl group, isopropoxycarbonyl group, normal butoxycarbonyl group, secondary butoxycarbonyl group, tertiary butoxycarbonyl group, normal pentyloxycarbonyl group, isopentyloxycarbonyl group, tertiary pentyloxycarbonyl group, neopentyloxycarbonyl group, 2,3-dimethylpropyloxycarbonyl group, 1-ethylpropyloxycarbonyl group, 1-methylbutyloxycarbonyl group, normal hexyloxycarbonyl group, isohexyloxycarbonyl group, or 1,1,2-trimethylpropyloxycarbonyl group.

[0015] The term "aryl group" refers to an aromatic hydrocarbon group having 6 to 10 carbon atoms, such as a phenyl group, a 1-naphthyl group, or a 2-naphthyl group.

[0016] Examples of salts of the benzimidazole compound represented by general formula (1) of the present invention include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate; organic acid salts such as acetate, fumarate, maleate, oxalate, methanesulfonate, benzenesulfonate, and paratoluenesulfonate; and salts with inorganic or organic bases such as sodium ion, potassium ion, calcium ion, and trimethylammonium.

[0017] The benzimidazole compound represented by general formula (1) of the present invention or a salt thereof may have one asymmetric center in its structural formula, and the present invention encompasses all optical isomers and mixtures containing these isomers in any ratio. The benzimidazole compound represented by general formula (1) of the present invention or a salt thereof may have two geometric isomers derived from a carbon-carbon double bond in its structural formula, and the present invention encompasses all geometric isomers and mixtures containing these isomers in any ratio. The benzimidazole compound represented by general formula (1) of the present invention or a salt thereof may have tautomers in its structural formula, and the present invention encompasses all tautomers and mixtures containing these isomers in any ratio.

[0018] In the benzimidazole compound represented by general formula (1) or a salt thereof, which is an active ingredient of the canine heartworm disease control agent of the present invention, R is preferably (a1) a hydrogen atom; (a2) a (C1-C6) alkyl group; (a3) ​​a halo(C1-C6) alkyl group; (a4) a (C2-C6) alkenyl group; (a5) a (C2-C6) alkynyl group; (a6) a (C1-C6) alkoxy(C1-C6) alkyl group; (a7) a (C1-C6) alkylthio(C1-C6) alkyl group; (a8) a (C1-C6) alkoxycarbonyl(C1-C6) alkyl group; (a9) a (C1-C6) alkoxycarbonyl group; (a10) an aryl(C1-C6) alkyl group; (a12) an aryl(C1-C6) alkoxy(C1-C6) alkyl group; or (a15) R 3 R 4 N carbonyl group (where R 3 and R 4 is the same as above. );(a16) R 3 R 4 N-thiocarbonyl group (where R 3 and R 4 is the same as above. ); or (a17) R 3 R 4 N sulfonyl group (where R 3 and R 4 is the same as above; X 1 and X 3 and preferably, both are (b1) a hydrogen atom; X 2(c1) a (C1-C8) alkyl group; (c3) a (C2-C8) alkynyl group; (c5) an aryl group having 1 to 5 substituents, which may be the same or different, selected from (a) a halogen atom, (b) a (C1-C6) alkyl group, (c) a halo(C1-C6) alkyl group, (d) a (C1-C6) alkoxy group, (e) a halo(C1-C6) alkoxy group, (f) a (C1-C6) alkylthio group, (g) a halo(C1-C6) alkylthio group, (h) a (C1-C6) alkylsulfinyl group, (i) a halo(C1-C6) alkylsulfinyl group, (l) a nitro group, and (m) a trimethylsilyl group; or (c7) aryl(C1-C6)alkyl groups having 1 to 5 substituents, which may be the same or different, selected from (a) halogen atoms, (b) (C1-C6)alkyl groups, (c) halo(C1-C6)alkyl groups, (d) (C1-C6)alkoxy groups, (e) halo(C1-C6)alkoxy groups, (f) (C1-C6)alkylthio groups, (g) halo(C1-C6)alkylthio groups, (h) (C1-C6)alkylsulfinyl groups, (i) halo(C1-C6)alkylsulfinyl groups, (j) (C1-C6)alkylsulfonyl groups, (k) halo(C1-C6)alkylsulfonyl groups, (l) nitro groups, and (m) trimethylsilyl groups; Y 1 and Y 4 are preferably the same or different and are (d1) a hydrogen atom; (d2) a halogen atom; or (d3) a (C1-C6) alkyl group; Y 2 and Y 3 are preferably, which may be the same or different, (e1) a hydrogen atom; (e2) a halogen atom; (e3) a (C1-C6) alkyl group; (e5) a (C1-C6) alkylthio group; (e6) a halo(C1-C6) alkyl group; (e7) a halo(C1-C6) alkoxy group; (e8) an aryloxy group; (e10) an arylthio group; or (e12) an arylcarbonyl group.

[0019] The benzimidazole compound represented by general formula (1) or a salt thereof, which is the active ingredient of the canine heartworm disease control agent of the present invention, can be produced, for example, by the following production method, but the present invention is not limited to these.

[0020] Manufacturing method 1 [ka]

[0021] Manufacturing method of step [A] The benzimidazole compound represented by general formula (1-5) can be produced by reacting an easily available benzimidazole compound represented by general formula (1-6) with a compound represented by PG-L (e.g., a protecting agent such as methoxymethyl chloride (MOMCl), methoxyethoxymethyl chloride (MEMCl), or 2-(trimethylsilyl)ethoxymethyl chloride (SEMCl)) in the presence of an inert solvent and a base.

[0022] Examples of the base used in this reaction include inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, and potassium hydride; acetates such as sodium acetate and potassium acetate; alkali metal alkoxides such as potassium t-butoxide, sodium methoxide, and sodium ethoxide; tertiary amines such as triethylamine, diisopropylethylamine, and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU); and nitrogen-containing aromatic compounds such as pyridine and dimethylaminopyridine (DMAP). The amount of the base used is usually in the range of 1 to 10 times the molar amount of the compound represented by general formula (1-6).

[0023] The inert solvent used in this reaction may be any solvent that does not significantly inhibit the progress of this reaction, and examples thereof include aromatic hydrocarbons such as benzene, toluene, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, etc.; halogenated aromatic hydrocarbons such as chlorobenzene, dichlorobenzene, etc.; chain or cyclic ethers such as diethyl ether, methyl tertiary butyl ether, dioxane, tetrahydrofuran (THF), etc.; esters such as ethyl acetate, amides such as dimethylformamide (DMF), dimethylacetamide (DMA), N-methylpyrrolidone (NMP), etc.; ketones such as acetone, methyl ethyl ketone, etc.; polar solvents such as dimethyl sulfoxide (DMSO), 1,3-dimethyl-2-imidazolidinone (DMI), etc.; and nitrogen-containing aromatic compounds such as pyridine. These inert solvents may be used alone or in combination.

[0024] Since this reaction is equimolar, each reactant may be used in equimolar amounts, but one of the reactants may be used in excess. The reaction temperature can range from room temperature to the boiling point of the inert solvent used, and the reaction time varies depending on the reaction scale and reaction temperature, but may be in the range of several minutes to 48 hours.

[0025] After completion of the reaction, the target product can be isolated from the reaction system containing the target product by a conventional method, and can be produced by purifying it, if necessary, by recrystallization, column chromatography, etc. Alternatively, the next step may be carried out without isolating the intermediate from the reaction system.

[0026] Manufacturing method of step [B] The benzimidazole compound represented by general formula (1-4) can be produced by reacting the benzimidazole compound represented by general formula (1-5) with the substituted imidazole compound represented by general formula (2) in the presence of an inert solvent and a base.

[0027] Examples of the base used in this reaction include inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, and sodium hydride; acetates such as sodium acetate and potassium acetate; alkali metal alkoxides such as potassium t-butoxide, sodium methoxide, and sodium ethoxide; tertiary amines such as triethylamine, diisopropylethylamine, and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU); and nitrogen-containing aromatic compounds such as pyridine and dimethylaminopyridine (DMAP). The amount of the base used is usually in the range of 1 to 10 times the molar amount of the compound represented by general formula (2).

[0028] The inert solvent that can be used in this reaction may be any solvent that does not significantly inhibit this reaction, and examples thereof include aromatic hydrocarbons such as benzene, toluene, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, etc.; halogenated aromatic hydrocarbons such as chlorobenzene, dichlorobenzene, etc.; linear or cyclic ethers such as diethyl ether, tetrahydrofuran (THF), dioxane, etc.; and amides such as dimethylformamide (DMF), dimethylacetamide (DMA), N-methylpyrrolidone (NMP), etc. These inert solvents can be used alone or in combination of two or more.

[0029] Since this reaction is equimolar, each reactant may be used in equimolar amounts, but one of the reactants may be used in excess. The reaction temperature can range from room temperature to the boiling point of the inert solvent used, and the reaction time varies depending on the reaction scale and reaction temperature, but may be in the range of several minutes to 48 hours.

[0030] After completion of the reaction, the target product can be isolated from the reaction system containing the target product by a conventional method, and can be produced by purifying it, if necessary, by recrystallization, column chromatography, etc. Alternatively, the next step may be carried out without isolating the intermediate from the reaction system.

[0031] Manufacturing method of step [C] The benzimidazole compound represented by general formula (1-3) can be produced by reacting the benzimidazole compound represented by general formula (1-4) with a phosphonium salt, a so-called Wittig reagent, produced by the reaction of triphenylphosphine with an arylalkyl halide in an inert solvent.

[0032] Examples of the base used in this reaction include inorganic bases such as sodium hydride, potassium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, and potassium bicarbonate, and the amount used is usually in the range of 1 to 10 times the molar amount of the compound represented by general formula (1-4).

[0033] The inert solvent that can be used in this reaction may be any solvent that does not significantly inhibit this reaction, and examples thereof include aromatic hydrocarbons such as benzene, toluene, and xylene; halogenated aromatic hydrocarbons such as chlorobenzene and dichlorobenzene; and chain or cyclic ethers such as diethyl ether, tetrahydrofuran (THF), and dioxane. These inert solvents can be used alone or in combination.

[0034] Since this reaction is equimolar, each reactant may be used in equimolar amounts, but one of the reactants may also be used in excess. The reaction temperature in this reaction is usually in the range of about 0°C to the boiling point of the solvent used, and the reaction time varies depending on the reaction scale, reaction temperature, etc., and is not constant, but may be appropriately selected in the range of several minutes to 48 hours.

[0035] After completion of the reaction, the target product can be isolated by a conventional method, and if necessary, purified by recrystallization, distillation, etc. Alternatively, the next step may be carried out without isolating the intermediate from the reaction system.

[0036] Manufacturing method of step [D] The protecting group of the benzimidazole compound represented by general formula (1-2) can be removed from the benzimidazole compound represented by general formula (1-3) according to the method described in Greene's PROTECTIVE GROUPS in ORGANIC SYNTHESIS (4th Edition) pp. 561-565, etc.

[0037] Manufacturing method of step [E] The benzimidazole compound represented by general formula (1-1) can be produced from the benzimidazole compound represented by general formula (1-2) in the presence of a reduction catalyst, under a hydrogen atmosphere, at normal pressure or under pressure, in the presence or absence of an inert solvent.

[0038] Examples of reduction catalysts include palladium catalysts such as palladium(0) / carbon and palladium hydroxide / carbon, and nickel catalysts such as Raney nickel. The amount of catalyst used may be appropriately selected from the range of 0.001 to 0.5 molar equivalents relative to the benzimidazole compound represented by general formula (1-2). The reaction temperature may be appropriately selected from the range of -20°C to the reflux temperature of the solvent used. The reaction time varies depending on the reaction scale, but may be appropriately selected from the range of several minutes to 100 hours.

[0039] The reaction pressure may be appropriately selected from the range of 0.1 MPa to 5 MPa. The inert solvent may be any solvent that does not significantly inhibit the progress of the reaction, and examples thereof include aliphatic hydrocarbons such as hexane, cyclohexane, and methylcyclohexane, aromatic hydrocarbons such as toluene, benzene, and chlorobenzene, amides such as dimethylformamide and dimethylacetamide, esters such as ethyl acetate and butyl acetate, alcohols such as methanol, ethanol, n-propanol, and i-propanol, organic acids such as 1,3-dimethyl-2-imidazolidinone, acetic acid, and propionic acid, and water. These inert solvents may be used alone or in combination.

[0040] After the reaction is complete, the target product can be isolated from the reaction system containing the target product by a conventional method, and if necessary, purified by recrystallization, column chromatography, distillation, etc. to produce the target product.

[0041] Manufacturing method of step [F] The benzimidazole compound represented by general formula (1) can be produced by reacting the benzimidazole compound represented by general formula (1-1) with a compound represented by RL (wherein L represents a leaving group such as a halogen atom) in the presence of an inert solvent and a base.

[0042] Examples of the base used in this reaction include inorganic bases such as sodium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, and potassium hydrogencarbonate, and acetates such as sodium acetate and potassium acetate, and the amount used is usually in the range of 1 to 10 times the molar amount of the compound represented by general formula (1-1). The compound represented by RL is usually used in an amount within a range of 1 to 10 times by mole relative to the compound represented by general formula (1-1).

[0043] The inert solvent that can be used in this reaction may be any solvent that does not significantly inhibit this reaction, and examples thereof include aromatic hydrocarbons such as benzene, toluene, and xylene; halogenated hydrocarbons such as methylene chloride, chloroform, and carbon tetrachloride; halogenated aromatic hydrocarbons such as chlorobenzene and dichlorobenzene; and chain or cyclic ethers such as diethyl ether, tetrahydrofuran (THF), and dioxane. These inert solvents can be used alone or in combination.

[0044] The reaction temperature in this reaction is usually in the range of about 0°C to the boiling point of the solvent used, and the reaction time varies depending on the reaction scale, reaction temperature, etc. and is not constant, but can be appropriately selected in the range of several minutes to 48 hours.

[0045] After the reaction is complete, the target product can be isolated by a conventional method, and if necessary, purified by recrystallization, distillation, etc. to produce the target product.

[0046] Next, specific examples of the compound of the present invention and its intermediates are shown below. In the table below, Me represents a methyl group, Et represents an ethyl group, n-Pro represents a normal propyl group, Ph represents a phenyl group, and Bn represents a benzyl group. Physical properties are shown in terms of melting point (°C) or H 1 -NMR is shown. 1 - NMR data are shown in Table 4.

[0047] [ka]

[0048] [Table 1]

[0049] [ka]

[0050] [Table 2]

[0051] [Table 3]

[0052] [Table 4]

[0053] The canine heartworm disease control agent of the present invention contains a benzimidazole compound represented by general formula (1) or a salt thereof as an active ingredient. The animals that can be treated with the canine heartworm disease control agent of the present invention are livestock such as cows, pigs, rabbits, and birds, or pets such as dogs, rabbits, and cats (hereinafter referred to as target animals, excluding humans), preferably dogs, but not limited to these. In the present invention, control includes prevention and treatment.

[0054] Heartworm disease is an infection caused by nematodes of the order Spirurida, in particular (a) nematodes of the family Onchocercidae, for example, Brugia spp., Brugia malayi, Brugia pahangi, Brugia patei; Dipetalonema spp., Dipetalonema reconditum; Dirofilaria spp., Dirofilaria immitis; Filaria spp., Filaria oculi; Onchocerca spp., Onchocerca cervicalis; (b) nematodes of the family Setariidae, for example, of the genus Setaria, Setaria digitata, Setaria equina, Setaria labiatopapillosa, Setaria marshalli; of the genus Wuchereria, Wuchereria bancrofti; (c) nematodes of the family Filariidae, for example, of the genus Parafilaria, Parafilaria multipapillosa; of the genus Stephanofilaria, for example,These diseases are known to be caused by, but not limited to, Stephanofilaria assamensis, Stephanofilaria dedoesi, Stephanofilaria kaeli, Stephanofilaria okinawaensis, and Stephanofilaria stilesi.

[0055] When using the pesticide of the present invention, the benzimidazole compound may be used as is without adding any other ingredients. However, it is usually preferable to further add excipients such as solid carriers or liquid carriers to the benzimidazole compound or its salts and formulate them into tablets, powders, granules, capsules, water-soluble formulations, solutions, wettable powders, suspensions, etc., according to conventional methods (e.g., the methods described in "Pharmaceutical Science," edited by Otsuka Akinobu et al., 1995, Nankodo Publishing). Examples of solid carrier excipients include lactose, sucrose, glucose, corn starch, gelatin, casein, starch, gum arabic, cellulose derivatives, alginic acid, etc. Examples of liquid carrier excipients include water, glycerin, vegetable oils, fatty acids, fatty acid esters, sorbitol, etc.

[0056] The pest control agent of the present invention may further contain, for example, organic minerals such as zinc peptide and iron peptide; inorganic minerals such as zinc carbonate, manganese carbonate, ferrous sulfate, and magnesium carbonate; vitamins such as vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, pantothenic acid, and nicotinic acid; alfalfa meal; and rolled corn. To enhance palatability, flavors and other additives may also be added. If necessary, conventional additives such as antibacterial agents, fungicides, anthelmintics, antioxidants, colorants, flavorings, and enzymes may be added. The agent is preferably formulated into powder, granules, liquids, tablets, and the like by conventional methods. These formulations may contain, as the active ingredient, a benzimidazole compound or a salt thereof, typically in an amount of about 0.01 to 95% by weight.

[0057] The control agent of the present invention thus formulated can be used as is or after diluting with water, etc. Furthermore, it may be used in combination with other conventional additives such as antibacterial agents, antifungal agents, anthelmintics, antioxidants, colorants, flavorings, and enzymes, either simultaneously or separately.

[0058] There are no particular limitations on the administration of the control agent of the present invention to target animals, and it can be administered by conventional methods such as sprinkling or mixing it into feed, as described below. The dose is an amount effective for controlling canine heartworm disease in target animals, i.e., an amount that, other conditions being equal, enhances the control effect of canine heartworm disease in target animals when the control agent of the present invention is administered compared to when it is not administered.

[0059] The method of mixing and gelling the active ingredients of the control agent of the present invention to be administered to target animals and allowing them to freely ingest the mixture can be carried out either at the hatchery or on the farm, and can also be carried out during the transportation of target animals from the hatchery to the farm.

[0060] Alternatively, a gelling preparation can be prepared by compounding the active ingredient of the control agent of the present invention with a predetermined amount of water-soluble polysaccharide powder, and when used in hatcheries and farms, this can be diluted with water to form a gel-like solid, which can then be administered to the target animals (i.e., ad libitum intake, direct administration into the crop).

[0061] The formulated control agent is usually used alone, but can also be diluted with water to prepare a diluted formulation (i.e., administered in drinking water). The active ingredient concentration in the diluted formulation is usually preferably in the range of about 10 to 10,000 ppm, more preferably about 35 to 5,000 ppm. The diluted formulation can be administered by dissolving about 0.01 to 500 g of the control agent in 1 L of water and applying the resulting solution. Preferably, about 0.035 to 350 g is dissolved in 1 L of water and administered.

[0062] The diluted formulation thus prepared can be administered to the target animals by using a drinking water dispenser, etc. The amount of the diluted formulation to be administered can be determined appropriately depending on the size, growth status, rearing density, and administration method of the target animals, but is usually preferably about 300 to 2000 liters per 10,000 birds.

[0063] The timing and duration of administration of the control agent of the present invention is such that, in egg-producing species and meat-producing species, it is administered continuously throughout the life of the target animals, preferably during the young chick stage (chickens 0 to 5 weeks old after hatching) or 0 to 5 weeks after birth.

[0064] The dosage of the control agent may be determined appropriately depending on the type and size of the target animal, but in general, the total dosage is preferably in the range of 0.005 to 2 g, more preferably 0.005 to 1 g.

[0065] The control composition of the present invention is prepared by adding the control agent to animal feed, drinking water, physiological electrolyte solutions, etc. The amount of the control agent added is preferably in the range of about 0.005 to 10.0% by weight based on the total amount of the control composition.

[0066] The target animal feed, drinking water or physiological electrolyte solution used in the control composition of the present invention is not particularly limited as long as it is a commonly used one. Examples of these include feeds prepared by appropriately mixing corn, rice, wheat, milo, soybean meal, bran, defatted rice bran, fish meal, skim milk powder, dried whey, oils and fats, alfalfa meal, North Pacific meal, soybean oil and fat, powdered refined beef tallow, wheat flour, rapeseed oil and fat, meat and bone meal (feather meal), animal fats and oils, calcium phosphate, corn gluten meal, molasses, corn germ meal, calcium carbonate, tricalcium phosphate, sodium chloride, choline chloride, vitamins (vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin D, vitamin E, calcium pantothenate, nicotinamide, folic acid, etc.), amino acids (lysine, methionine, etc.), trace inorganic salts (magnesium sulfate, ferrous sulfate, copper sulfate, zinc sulfate, potassium iodide, cobalt sulfate, etc.), probiotics, etc.

[0067] The pest control composition of the present invention may further contain, for example, organic minerals such as zinc peptide and iron peptide, inorganic minerals such as zinc carbonate, manganese carbonate, iron sulfate and magnesium carbonate, vitamins such as vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, pantothenic acid and nicotinic acid, alfalfa meal, rolled corn, etc. Furthermore, to increase palatability, flavors and the like may be added at the same time.

[0068] There are no particular limitations on the method of administering the control composition of the present invention to target animals, and it can be administered by any appropriate method, such as sprinkling or mixing it into feed, as described below. The amount of the control composition to be administered is, in short, an amount effective for controlling heartworm disease in target animals, that is, an amount at which, other conditions being equal, the effect of controlling heartworm disease in target animals is enhanced when the control composition of the present invention is administered compared to when it is not administered.

[0069] The timing and duration of administration of the control agent composition of the present invention is such that, in egg-producing species and meat-producing species, the composition is administered continuously throughout the entire life of the target animals, preferably during the young chick stage (chickens 0 to 5 weeks old after hatching) or 0 to 5 weeks after birth, and more preferably for 0 to 21 days after hatching or for 0 to 21 days after birth.

[0070] When the control agent composition of the present invention is used by being added to feed for target animals, the benzimidazole compound or its salt can be used in a proportion of about 0.0005 to 5% by weight, preferably about 0.05 to 2% by weight, and when added to drinking water or physiological electrolyte solutions, the benzimidazole compound or its salt can be used in a proportion of about 0.035 to 3.5% by weight, preferably about 0.035 to 1.4% by weight.

[0071] The control method of the present invention comprises a step of administering an effective amount of the control agent or control composition of the present invention to a target animal. In this method, the control composition can be administered to the animal in a conventional manner. The effective amount varies depending on the type of formulation, the target animal, the administration period, and other factors, and can be increased or decreased as appropriate without regard to the above range.

[0072] Specifically, for example, the control agent of the present invention is diluted with water to a concentration suitable for administration to target animals, and the resulting diluted solution is administered to the target animals. The dilution ratio may be applied in accordance with conventional methods for diluting and administering via drinking water; for example, a 5- to 10-fold dilution is preferably used. Alternatively, the control agent of the present invention may be diluted with water to a predetermined concentration, to which a water-soluble polysaccharide is added under stirring to form a homogeneous solution. The solution is then allowed to stand at room temperature or stored in a cool place (e.g., a refrigerator) to obtain a gel-like solid. Alternatively, when using a gelling agent (e.g., agar, gelatin, etc.) that dissolves at high temperatures and solidifies at low temperatures, the gelling agent is added to the medium used to prepare the control agent of the present invention, and the medium is sterilized by high-pressure steam, cooled, and then allowed to stand at room temperature or stored in a cool place (e.g., a refrigerator) to obtain a gel-like solid. The gel-like solid obtained in this manner may be administered to target animals. The gel strength of the gel is approximately 200 to 2,000 g / cm. 2 is appropriate, and when agar is used, this corresponds to a concentration of roughly 0.5 to 3.0%, although this differs depending on the type of agar.

[0073] Examples of polysaccharides used to gel the control agent of the present invention in an aqueous medium include agar, carrageenan, carboxymethylcellulose, starch, mannan, gelatin, sodium alginate, gum arabic, wax bean gum, xanthan gum, chitosan, guar gum, pectin, propyl glycol alginate, arabinogalactan, gum ghatti, tamarind seed gum, pullulan, morpholine fatty acid salts, curdlan, tragacanth gum, etc. Among these polysaccharides, it is particularly preferable to use agar, starch, mannan, and gelatin because they are inexpensive and easily available.

[0074] For example, when the gelled solid is administered to poultry, typically 0 to 7 days old and with low water and feed intake, the poultry's genetic program (habit) of pecking at solids on the floor to consume them allows them to efficiently ingest the necessary amount of the pesticide of the present invention in a short period of time. In this case, live bacterial agents, vaccines, drugs, nutrients, etc., which are difficult to administer to young poultry, can also be efficiently administered to poultry simultaneously with the pesticide of the present invention by mixing them with the pesticide of the present invention and gelling them with a water-soluble polysaccharide. Furthermore, providing chicks with water and nutrients is extremely important for subsequent productivity. Nutrients include carbohydrates, such as monosaccharides (e.g., glucose, mannose, fructose) and their oligosaccharides, and disaccharides (e.g., sucrose), proteins (e.g., skim milk), lipids, as well as vitamins and minerals.

[0075] Furthermore, in order to reinforce or complement the effect of the canine heartworm disease control agent of the present invention, an existing canine heartworm disease control agent can be used in combination. When using them in combination, two or more active ingredients may be mixed before administration, or two or more different formulations may be administered separately. [Example]

[0076] The present invention will be explained in more detail below with reference to production examples, formulation examples and test examples, but the present invention is not limited to these examples in any way.

[0077] Reference Example 1. Method for preparing 1-methoxymethyl-2-(4-formyl-1H-imidazol-1-yl)benzimidazole [ka] 1-Methoxymethyl-2-chlorobenzimidazole (10 g, 50 mmol), 4-formyl-1H-imidazole (5.5 g, 1.1 equivalents), and potassium carbonate (21 g, 3 equivalents) were added to NMP (50 mL) and reacted at 120°C for 3 hours. After cooling to room temperature, water was added and extraction with ethyl acetate was performed. The organic layer was washed with saturated brine and dried over sodium sulfate. After distilling off the solvent, the product was purified by column chromatography to obtain the target product (6.0 g, yield 47%).

[0078] Reference Example 2. Method for preparing 1-methoxymethyl-2-(4-(2-(2,4-dichlorophenyl)vinyl)-1H-imidazol-1-yl)benzimidazole [ka] 1-Methoxymethyl-2-(4-formyl-1H-imidazol-1-yl)benzimidazole (1.0 g, 4.0 mmol) was added to THF (20 mL), and 2,4-dichlorobenzyltriphenylphosphonium chloride (2.2 g, 1.2 equivalents) and 60% sodium hydride (0.24 g, 1.5 equivalents) were added. The mixture was then heated to 50°C and reacted for 2 hours. After cooling to room temperature, water was added to quench the reaction and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over sodium sulfate. The solvent was evaporated to give the desired product (1.3 g, 81% yield).

[0079] Reference Example 3. Method for producing 2-(4-(2-(2,4-dichlorophenyl)vinyl)-1H-imidazol-1-yl)benzimidazole [ka] 1-Methoxymethyl-2-(4-(2-(2,4-dichlorophenyl)vinyl)-1H-imidazol-1-yl)benzimidazole (1.3 g, 3.2 mmol) was added to THF (20 mL), and concentrated hydrochloric acid (10 mL) was added. The mixture was then allowed to react under reflux for 2 hours. After cooling to room temperature, the mixture was neutralized with an aqueous potassium carbonate solution and extracted with ethyl acetate. The organic layer was washed with saturated saline and dried over sodium sulfate. The solvent was evaporated to obtain the target product.

[0080] Example 1. Method for preparing 2-(4-(2-(2,4-dichlorophenyl)ethyl)-1H-imidazol-1-yl)benzimidazole (Compound No. 1-1) [ka] The 2-(4-(2-(2,4-dichlorophenyl)vinyl)-1H-imidazol-1-yl)benzimidazole obtained in the previous step was added to ethanol (20 mL), and 5% Pd / C (0.34 g) was added. The atmosphere in the reactor was replaced with hydrogen, and the reaction was carried out at room temperature for 3 hours under a hydrogen atmosphere of 0.4 MPa. The reaction solution was filtered through Celite to remove the Pd / C, and the filtrate was concentrated to obtain the target product (0.35 g, 31% yield (from the previous step)).

[0081] Intermediate Production Example 1. Method for producing 2-chloro-1-methoxymethylbenzimidazole [ka] 2-Chlorobenzimidazole (10.0 g, 74.6 mmol) was dissolved in DMA (60 mL) and sodium hydride (3.58 g, 1.2 equiv.) was added in several portions at room temperature. After 5 minutes of reaction, MOMCl (chloromethyl methyl ether) (7.8 g, 1.3 equiv.) was added at room temperature. After 3 hours of reaction at room temperature, the reaction was quenched with water. Extraction was performed with ethyl acetate, the organic layer was dried over magnesium sulfate, and the solvent was evaporated. The resulting crude product was purified by column chromatography to obtain the desired product (13.6 g, 93% yield).

[0082] Formulation example 1. Powder 25 parts of the benzimidazole compound and 25 parts of lactose are thoroughly mixed in a mortar, and the mixture is then thoroughly stirred and mixed to obtain a powder.

[0083] Formulation example 2: Granules 25 parts of the benzimidazole compound and 25 parts of lactose are added and thoroughly mixed. Then, an appropriate amount of water is added to the mixture, and after further stirring, the mixture is granulated in a granulator and air-dried to obtain granules.

[0084] Formulation example 3. Wettable powder 25 parts of a benzimidazole compound, 65 parts of diatomaceous earth, 5 parts of a higher alcohol sulfate, and 5% of an alkylnaphthalene sulfonate are uniformly mixed and finely pulverized to obtain a wettable powder.

[0085] Test Example 1. Test to evaluate the effect on the movement of dog heartworm (Dirofilaria immitis) larvae Five hundred L-1 stage larvae of Dirofilaria immitis diluted in a prescribed preparation solution were inoculated into each well of a 96-well plate, and a DMSO diluted solution of the benzimidazole compound represented by general formula (1) of the present invention or its salt was added to a final concentration of 50 ppm. The plate was then left to stand for 3 days, and their motility was examined. The motility inhibition rate of each treatment group was corrected and calculated based on the inhibitory effect of the DMSO solution alone, and evaluated according to the following criteria.

[0086] Judgment criteria A Corrected movement inhibition rate 100% B. Correction movement inhibition rate: 99% to 90% C... Corrected movement inhibition rate 89%~80% D Corrected movement inhibition rate: 79% to 50%

[0087] As a result, the compound 1-1 of the present invention exhibited activity A.

[0088] Test Example 2: Evaluation test of the effect on the growth of dog heartworms (Dirofilaria immitis) A 24-well plate was plated with a predetermined preparation solution, 8 to 20 L-3 stage larvae of Dirofilaria immitis, and a DMSO diluted solution of the benzimidazole compound of the present invention, each well being a final concentration of 50 ppm. Seven days later, the number of larvae that had developed to the L-4 stage was counted, and the rate of inhibition of growth from the L3 stage to the L4 stage was calculated.

[0089] As a result, among the compounds represented by the general formula (1) of the present invention, compound numbers 2-2, 2-9, 2-10, 2-17, 2-18, and 2-26 showed a growth inhibition rate of 50% or more. [Industrial Applicability]

[0090] The present invention can provide a canine heartworm disease control agent for target animals that exerts an excellent effect when administered to target animals, and a method for using the canine heartworm disease control agent for target animals using the same.

Claims

1. General formula (1) 【Chemistry 1】 {During the ceremony, R is (a1) a hydrogen atom; (a2) (C 1 -C 6 ) alkyl group; (a3) Halo (C 1 -C 6 ) alkyl group; (a4) (C 2 -C 6 ) alkenyl group; (a5) (C 2 -C 6 ) an alkynyl group; (a6) (C 1 -C 6 ) Alkoxy (C 1 -C 6 ) alkyl group; (a7) (C 1 -C 6 ) alkylthio (C 1 -C 6 ) alkyl group; (a8) (C 1 -C 6 ) alkoxycarbonyl (C 1 -C 6 ) alkyl group; (a9) (C 1 -C 6 ) an alkoxycarbonyl group; (a10) Aryl (C 1 -C 6 ) alkyl group; (a11) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 ) an aryl group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group. 1 -C 6 ) alkyl group; (a12) Aryl (C 1 -C 6 ) Alkoxy (C 1 -C 6 ) alkyl group; (a13) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 ) an aryl group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group (C 1 -C 6 ) Alkoxy (C 1 -C 6 ) alkyl group; (a14) R 3 R 4 N group (where R 3 and R 4 may be the same or different, (aa) a hydrogen atom, (ab) (C 1 -C 6 ) alkyl group, (ac) (C 1 -C 6 ) an alkoxy group, (ad) (C 1 -C 6 ) an alkoxycarbonyl group, (ae) (C 1 -C 6 ) alkylsulfonyl group, (af) halo (C 1 -C 6 ) an alkylsulfonyl group, or (ag) a phenyl group; (a15) R 3 R 4 N carbonyl group (where R 3 and R 4 is the same as above.) (a16) R 3 R 4 N-thiocarbonyl group (where R 3 and R 4 is the same as above; or (a17) R 3 R 4 N sulfonyl group (where R 3 and R 4 is the same as above.) ; X 1 and X 3 may be the same or different, (b1) a hydrogen atom; (b2) a halogen atom; or (b3) (C 1 -C 6 ) alkyl group; X 2 teeth, (c1) (C 1 -C 8 ) alkyl group; (c2) (C 2 -C 8 ) alkenyl group; (c3) (C 2 -C 8 ) an alkynyl group; (c4) an aryl group; (c5) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 (l) an aryl group having 1 to 5 substituents selected from an alkylsulfinyl group, a nitro group, and (m) a trimethylsilyl group; (c6) aryl (C 1 -C 6 ) alkyl group; or (c7) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 ) an aryl group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group (C 1 -C 6 ) alkyl group; Y 1 and Y 4 may be the same or different, (d1) a hydrogen atom; (d2) a halogen atom; or (d3) (C 1 -C 6 ) alkyl group; Y 2 and Y 3 may be the same or different, (e1) a hydrogen atom; (e2) a halogen atom; (e3) (C 1 -C 6 ) alkyl group; (e4) (C 1 -C 6 ) an alkoxy group; (e5) (C 1 -C 6 ) an alkylthio group; (e6) Halo (C 1 -C 6 ) alkyl group; (e7) Halo (C 1 -C 6 ) an alkoxy group; (e8) an aryloxy group; (e9) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 (l) an aryloxy group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group; (e10) an arylthio group; (e11) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 (l) an arylthio group having 1 to 5 substituents selected from an alkylsulfonyl group, a nitro group, and (m) a trimethylsilyl group; (e12) an arylcarbonyl group; or (e13) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 (l) an arylcarbonyl group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group. or a salt thereof.

2. R is, (a1) a hydrogen atom; (a2) (C 1 -C 6 ) alkyl group; (a3) Halo (C 1 -C 6 ) alkyl group; (a4) (C 2 -C 6 ) alkenyl group; (a5) (C 2 -C 6 ) an alkynyl group; (a6) (C 1 -C 6 ) Alkoxy (C 1 -C 6 ) alkyl group; (a7) (C 1 -C 6 ) alkylthio (C 1 -C 6 ) alkyl group; (a8) (C 1 -C 6 ) alkoxycarbonyl (C 1 -C 6 ) alkyl group; (a9) (C 1 -C 6 ) an alkoxycarbonyl group; (a10) Aryl (C 1 -C 6 ) alkyl group; (a12) Aryl (C 1 -C 6 ) Alkoxy (C 1 -C 6 ) alkyl group; (a15) R 3 R 4 N carbonyl group (where R 3 and R 4 is the same as above.) (a16) R 3 R 4 N-thiocarbonyl group (where R 3 and R 4 is the same as above; or (a17) R 3 R 4 N sulfonyl group (where R 3 and R 4 is the same as above.) X 1 and X 3 Both of them represent (b1) a hydrogen atom; X 2 but, (c1) (C 1 -C 8 ) alkyl group; (c3) (C 2 -C 8 ) an alkynyl group; (c5) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an aryl group having 1 to 5 substituents selected from an alkylsulfinyl group, (l) a nitro group, and (m) a trimethylsilyl group; or (c7) may be the same or different, (a) a halogen atom, (b) (C 1 -C 6 ) alkyl group, (c) halo (C 1 -C 6 ) alkyl group, (d) (C 1 -C 6 ) alkoxy group, (e) halo (C 1 -C 6 ) an alkoxy group, (f) (C 1 -C 6 ) alkylthio group, (g) halo (C 1 -C 6 ) an alkylthio group, (h) (C 1 -C 6 ) alkylsulfinyl group, (i) halo (C 1 -C 6 ) an alkylsulfinyl group, (j) (C 1 -C 6 ) alkylsulfonyl group, (k) halo (C 1 -C 6 ) an aryl group having 1 to 5 substituents selected from an alkylsulfonyl group, (l) a nitro group, and (m) a trimethylsilyl group (C 1 -C 6 ) alkyl group; Y 1 and Y 4 may be the same or different, (d1) a hydrogen atom; (d2) a halogen atom; or (d3) (C 1 -C 6 ) alkyl group; Y 2 and Y 3 may be the same or different, (e1) a hydrogen atom; (e2) a halogen atom; (e3) (C 1 -C 6 ) alkyl group; (e5) (C 1 -C 6 ) an alkylthio group; (e6) Halo (C 1 -C 6 ) alkyl group; (e7) Halo (C 1 -C 6 ) an alkoxy group; (e8) an aryloxy group; (e10) an arylthio group; or (e12) an arylcarbonyl group; The benzimidazole compound or a salt thereof according to claim 1.

3. 3. An animal control agent for heartworm disease, comprising the benzimidazole compound or a salt thereof according to claim 1 as an active ingredient.

4. Use of the benzimidazole compound or a salt thereof according to any one of claims 1 to 2 for the manufacture of an agent for controlling heartworm disease in animals.

Citation Information

Patent Citations

  • Prevention of dog against filariasis

    JP1980035055A

  • Benzimidazole derivative and agricultural and horticultural germicide

    JP1989063580A

  • Benzimidazole compound or salt thereof, agricultural and horticultural insecticidal and acaricidal agent containing said compound, and method for using same

    WO2019225663A1

  • Benzimidazole compound or salt thereof, agricultural and horticultural insecticidal and acaricidal agent comprising said compound, and method for using said insecticidal and acaricidal agent

    WO2021107110A1